🇺🇸 FDA
Patent

US 11905285

Inhibitors of plasma kallikrein and uses thereof

granted A61PA61P7/10

Quick answer

US patent 11905285 (Inhibitors of plasma kallikrein and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P7/10